Status:
COMPLETED
An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)
Lead Sponsor:
Chiba University
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
6-17 years
Phase:
PHASE2
Brief Summary
Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action (like the Tipepidine H...
Eligibility Criteria
Inclusion
- \[Inclusion Criteria\]
- Attention-Deficit/Hyperactivity Disorder (AD/HD) for DSM-IV TR criteria.
- Patients are treated with Atomoxetine, Methylphenidate, atypical antipsychotic drugs (risperidone, olanzapine, quetiapine, perospirone, aripiprazole, blonanserin, paliperidone) or not treated.
- Patients are stable for 4-weeks for medication.
- \[Exclusion Criteria\]
- Patients with a previous hypersensitivity to Tipepidine Hibenzate.
- Patients treated with typical antipsychotics and selective norepinephrine reuptake inhibitor (NRI) except atomoxetine and stimulants except methylphenidate.
- Pregnant or breast-feeding women
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01835093
Start Date
April 1 2013
End Date
February 1 2014
Last Update
February 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, Chiba University School of Medicine
Chiba, Chuo-ku, Japan, 260-8670